|
1
|
Buchynskyi M, Oksenych V, Kamyshna I, Budarna O, Halabitska I, Petakh P, Kamyshnyi O. Genomic insight into COVID-19 severity in MAFLD patients: a single-center prospective cohort study. Front Genet 2024; 15:1460318. [PMID: 39296547 PMCID: PMC11408174 DOI: 10.3389/fgene.2024.1460318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2024] [Accepted: 08/23/2024] [Indexed: 09/21/2024] Open
Abstract
This study investigated the influence of single nucleotide polymorphisms (SNPs) in genes associated with the interferon pathway (IFNAR2 rs2236757), antiviral response (OAS1 rs10774671, OAS3 rs10735079), and viral entry (ACE2 rs2074192) on COVID-19 severity and their association with nonalcoholic fatty liver disease (MAFLD). We did not observe a significant association between the investigated SNPs and COVID-19 severity. While the IFNAR2 rs2236757 A allele was correlated with higher creatinine levels upon admission and the G allele was correlated with lower band neutrophils upon discharge, these findings require further investigation. The distribution of OAS gene polymorphisms (rs10774671 and rs10735079) did not differ between MAFLD patients and non-MAFLD patients. Our study population's distribution of ACE2 rs2074192 genotypes and alleles differed from that of the European reference population. Overall, our findings suggest that these specific SNPs may not be major contributors to COVID-19 severity in our patient population, highlighting the potential role of other genetic factors and environmental influences.
Collapse
Affiliation(s)
- Mykhailo Buchynskyi
- Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Valentyn Oksenych
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Iryna Kamyshna
- Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Olena Budarna
- Department of Neurology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Iryna Halabitska
- Department of Therapy and Family Medicine, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Pavlo Petakh
- Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
- Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine
| | - Oleksandr Kamyshnyi
- Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| |
Collapse
|
|
2
|
Perez-Favila A, Sanchez-Macias S, De Lara SAO, Garza-Veloz I, Araujo-Espino R, Castañeda-Lopez ME, Mauricio-Gonzalez A, Vazquez-Reyes S, Velasco-Elizondo P, Trejo-Ortiz PM, Montaño FEM, Castruita-De la Rosa C, Martinez-Fierro ML. Gene Variants of the OAS/RNase L Pathway and Their Association with Severity of Symptoms and Outcome of SARS-CoV-2 Infection. J Pers Med 2024; 14:426. [PMID: 38673053 PMCID: PMC11051515 DOI: 10.3390/jpm14040426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2024] [Revised: 04/05/2024] [Accepted: 04/15/2024] [Indexed: 04/28/2024] Open
Abstract
INTRODUCTION The interferon pathway plays a critical role in triggering the immune response to SARS-CoV-2, and these gene variants may be involved in the severity of COVID-19. This study aimed to analyze the frequency of three gene variants of OAS and RNASEL with the occurrence of COVID-19 symptoms and disease outcome. METHODS This cross-sectional study included 104 patients with SARS-CoV-2 infection, of which 34 were asymptomatic COVID-19, and 70 were symptomatic cases. The variants rs486907 (RNASEL), rs10774671 (OAS1), rs1293767 (OAS2), and rs2285932 (OAS3) were screened and discriminated using a predesigned 5'-nuclease assay with TaqMan probes. RESULTS Patients with the allele C of the OAS2 gene rs1293767 (OR = 0.36, 95% CI: 0.15-0.83, p = 0.014) and allele T of the OAS3 gene rs2285932 (OR = 0.39, 95% CI: 0.2-0.023, p = 0.023) have lower susceptibility to developing symptomatic COVID-19. The genotype frequencies (G/G, G/C, and C/C) of rs1293767 for that comparison were 64.7%, 29.4%, and 5.9% in the asymptomatic group and 95.2%, 4.8%, and 0% in severe disease (p < 0.05). CONCLUSIONS Our data indicate that individuals carrying the C allele of the OAS2 gene rs1293767 and the T allele of the OAS3 gene rs2285932 are less likely to develop symptomatic COVID-19, suggesting these genetic variations may confer a protective effect among the Mexican study population. Furthermore, the observed differences in genotype frequencies between asymptomatic individuals and those with severe disease emphasize the potential of these variants as markers for disease severity. These insights enhance our understanding of the genetic factors that may influence the course of COVID-19 and underscore the potential for genetic screening in identifying individuals at increased risk for severe disease outcomes.
Collapse
Affiliation(s)
- Aurelio Perez-Favila
- Laboratorio de Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (A.P.-F.); (S.S.-M.); (S.A.O.D.L.); (I.G.-V.); (C.C.-D.l.R.)
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Sonia Sanchez-Macias
- Laboratorio de Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (A.P.-F.); (S.S.-M.); (S.A.O.D.L.); (I.G.-V.); (C.C.-D.l.R.)
| | - Sergio A. Oropeza De Lara
- Laboratorio de Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (A.P.-F.); (S.S.-M.); (S.A.O.D.L.); (I.G.-V.); (C.C.-D.l.R.)
| | - Idalia Garza-Veloz
- Laboratorio de Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (A.P.-F.); (S.S.-M.); (S.A.O.D.L.); (I.G.-V.); (C.C.-D.l.R.)
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Roxana Araujo-Espino
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Maria E. Castañeda-Lopez
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Alejandro Mauricio-Gonzalez
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Sodel Vazquez-Reyes
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Perla Velasco-Elizondo
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Perla M. Trejo-Ortiz
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Fabiana E. Mollinedo Montaño
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| | - Claudia Castruita-De la Rosa
- Laboratorio de Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (A.P.-F.); (S.S.-M.); (S.A.O.D.L.); (I.G.-V.); (C.C.-D.l.R.)
| | - Margarita L. Martinez-Fierro
- Laboratorio de Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (A.P.-F.); (S.S.-M.); (S.A.O.D.L.); (I.G.-V.); (C.C.-D.l.R.)
- Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (R.A.-E.); (M.E.C.-L.); (A.M.-G.); (S.V.-R.); (P.V.-E.); (P.M.T.-O.); (F.E.M.M.)
| |
Collapse
|
|
3
|
Shmanko VV, Pidruchna SR, Hnizdyukh RV, Mudra AE, Zakharchuk UM, Kuzmak IP, Yaroshenko TY, Palytsya LM, Bandas IA, Dzhyvak VH, Nikitina IM, Zavarynska IF. Changes in lipid profile parameters depending on the a1166c polymorphism of the angiotensin II type I receptor gene as a predictor of arterial hypertension. WIADOMOSCI LEKARSKIE (WARSAW, POLAND : 1960) 2024; 77:1554-1561. [PMID: 39231326 DOI: 10.36740/wlek202408104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/06/2024]
Abstract
OBJECTIVE Aim: To investigate lipid profile parameters depending the polymorphism of the A1166C I type gene receptor of the angiotensin II as a predictor of arterial hypertension. PATIENTS AND METHODS Materials and Methods: The study involved 86 patients with arterial hypertension. The control group consisted of 30 practically healthy individuals. Indicators of lipid metabolism in the blood serum of patients were determined using "Lachema" kits on an analyzer. The the polymorphism of the A1166C I type gene receptor of the angiotensin II was studied by polymerase chain reaction with electrophoretic detection of the results. RESULTS Results: Higher levels of total cholesterol were found in patients with CC genotype compared to AA genotype carriers ((8.94±0.09) vs (5.18±0.02) mmol/L). The level of low-density lipoprotein in CC-genotype carriers was (7.43±0.03) versus (3.66±0.02) mmol/L in A-allele homozygotes. Triglycerides and very low density lipoproteins were also significantly higher in CC genotype carriers compared to patients with AA genotype. The level of high-density lipoprotein was lower in homozygotes with C-allele than in patients with the AA genotype, and was (0.59±0.12) versus (0.99±0.03) mmol/L. CONCLUSION Conclusions: The presence in the CC genotype the I type gene receptor of the angiotensin II type is a predictor of dyslipidemia. In patients with arterial hypertension, the presence in the C-allele of the I type gene of the angiotensin II type contributes to a significant increase in serum adipokines and a decrease in ghrelin levels.
Collapse
Affiliation(s)
| | | | - Roman V Hnizdyukh
- I. YA. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
| | - Alla E Mudra
- I. YA. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
| | | | - Iryna P Kuzmak
- I. YA. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
| | | | - Lylya M Palytsya
- I. YA. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
| | - Iryna A Bandas
- I. YA. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
| | | | | | - Iryna F Zavarynska
- TERNOPIL VOLODYMYR HNATIUK NATIONAL PEDAGOGICAL UNIVERSITY, TERNOPIL, UKRAINE
| |
Collapse
|
|
4
|
Demirhan S, Goldman DL, Herold BC. Differences in the Clinical Manifestations and Host Immune Responses to SARS-CoV-2 Variants in Children Compared to Adults. J Clin Med 2023; 13:128. [PMID: 38202135 PMCID: PMC10780117 DOI: 10.3390/jcm13010128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 12/20/2023] [Accepted: 12/22/2023] [Indexed: 01/12/2024] Open
Abstract
The COVID-19 pandemic challenged the medical field to rapidly identify and implement new approaches to the diagnosis, treatment and prevention of SARS-CoV-2 infections. The scientific community also needed to rapidly initiate basic, translational, clinical and epidemiological studies to understand the pathophysiology of this new family of viruses, which continues to evolve with the emergence of new genetic variants. One of the earliest clinical observations that provided a framework for the research was the finding that, in contrast to most other respiratory viruses, children developed less severe acute and post-acute disease compared to adults. Although the clinical manifestations of SARS-CoV-2 infection changed with each new wave of the pandemic, which was dominated by evolving viral variants, the differences in severity between children and adults persisted. Comparative immunologic studies have shown that children mount a more vigorous local innate response characterized by the activation of interferon pathways and recruitment of innate cells to the mucosa, which may mitigate against the hyperinflammatory adaptive response and systemic cytokine release that likely contributed to more severe outcomes including acute respiratory distress syndrome in adults. In this review, the clinical manifestations and immunologic responses in children during the different waves of COVID-19 are discussed.
Collapse
Affiliation(s)
| | | | - Betsy C. Herold
- Department of Pediatrics, Division of Infectious Diseases, Albert Einstein College of Medicine, The Children’s Hospital at Montefiore, 1225 Morris Park Avenue, Bronx, NY 10461, USA; (S.D.); (D.L.G.)
| |
Collapse
|